Clear Search

Showing 3 results for “Touma Z”.

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study

Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685

Proof-of-concept study for the safety and efficacy of filgotinib (FIL) and lanraplenib (LANRA) in cutaneous lupus (CLE) fails to meet primary endpoint, but select subgroups displayed a numerically greater treatment response to FIL relative to placebo.

Read more…

Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Arthritis Care Res (Hoboken). 2021 Dec 28. Epub ahead of print

Study identifies shifts in the paradigm of systemic lupus erythematosus (SLE) damage and develops a unifying conceptual framework to inform development of a revised SLE Damage Index (SDI).

Shifts in the concept of damage in SLE have occurred with new insights into disease manifestations, diagnostics, and therapy. Consequently, there is a need for a revised SDI, to incorporate additional factors that contribute to damage accrual.

Read more…

Real-world Impact of Flaring on Patient-Reported Outcomes and Healthcare Resource Utilisation in Systemic Lupus Erythematosus

Clin Exp Rheumatol. 2021.Epub ahead of print

Data from the real world underscores the need for more effective strategies and treatments to alleviate or prevent flaring in systemic lupus erythematosus (SLE).

Despite data from Hong Kong and Canada showing an association of flaring with reduced health-related quality of life and increased healthcare resourse utilisation and costs, similar international data are limited.

Read more…